BIONEWS
Parabilis raises $670M, betting the full-stack biotech is back
Two months after Kailera's $625M obesity drug IPO, cancer drug maker Parabilis priced its own record deal and named the playbook it intends to fund.
Two months after Kailera's $625M obesity drug IPO, cancer drug maker Parabilis priced its own record deal and named the playbook it intends to fund.
Parabilis Medicines priced 33.5 million shares at $20 each on Tuesday morning, raising $670 million in an upsized initial public offering, according to Fierce Biotech, which cited a Parabilis company release. Underwriters retain a 30-day option to sell another 5 million shares at the IPO price, which would push gross proceeds to roughly $770 million. Shares are set to trade on Nasdaq under the ticker PBLS.
Fierce Biotech's report frames the deal as the largest biotech IPO in sector history. That "record" claim traces to a Parabilis company release rather than independent verification, and it will only harden once the S-1 lands. The same wire notes the company had earlier in the week targeted $553 million and, before that, $476 million of net proceeds. Demand outran each revised ceiling.
The story behind the number is what makes the deal worth tracking. Parabilis, formerly known as FogPharma, is a cancer-drug developer working on the Wnt/β-catenin pathway, a cell-signaling route long implicated in tumor growth. Its lead asset, zolucatetide, is being developed first for desmoid tumors, a rare connective-tissue cancer. In a quote carried by Fierce Biotech, CEO Mathai Mammen said the company plans to be a "big, important company" with research, manufacturing, and commercialization all under one roof.
That last sentence is what the IPO is actually funding. For most of the past decade, the dominant biotech model was the opposite: stay lean, stay virtual, partner out the manufacturing, license out the launch. The capital-efficient startup. Parabilis is now raising a record sum in the public markets to do the thing the sector had collectively walked away from. If Mammen's plan works, the IPO is a vote that the integrated, full-stack biopharma playbook, where one company runs the lab, the factory, and the sales force, is investable again.
The comparison that gives the thesis weight is Kailera Therapeutics. Roughly two months before Parabilis priced, the obesity-focused developer Kailera raised $625 million in what was, at the time, the largest biotech IPO in history, according to the same Fierce Biotech coverage. Kailera is building out its own next-generation obesity drugs rather than handing them off to a larger partner. Two record biotech IPOs in sixty days, both for companies that want to own more of their own stack, is a pattern worth tracking on its own: capital appears to be rotating back toward integrated builders.
There is real tension underneath the optimism. The lead asset, zolucatetide, is still early-stage. Desmoid tumors are rare, and Wnt-pathway drugs have a long history of difficult biology. The $670 million, potentially $770 million, is not a single-program fund. It is a runway for a platform, a manufacturing build-out, and a commercial organization that does not yet exist. Mammen's vision only works if the early data holds and if the next round of capital does not price the same way.
What to watch next: the S-1 and 424B5 prospectus, expected around listing, will spell out the share count, the underwriter syndicate, and the precise use of proceeds. The first analyst day will show whether Parabilis positions itself as a one-asset company with a Wnt platform or as a diversified oncology house. And Kailera's post-IPO data drops, expected later in 2026, will show whether the integrated-model bet survives contact with a real readout.
For now, the check has been written. The question is whether the model it is funding can clear its own bar.